Pulmatrix Inc (NASDAQ: PULM), a clinical-stage biopharmaceutical company, announced on Tuesday that it has appointed Anand Varadan as its new director, effective 26 July 2021.

Presently, Vardan serves as executive vice president, chief commercial officer at Chiasma (NYSE: CHMA). He has earlier served as strategic advisor and chief commercial officer at Chiasma. Previously, he held the position of executive vice president, chief commercial officer of Karyopharm Therapeutics Inc.

Vardan also offers commercial and strategic consultancy services through his consulting firm, Ignition Insights LLC and has served in management and commercial leadership roles at biopharmaceutical company Amgen Inc in the US, European Union and Canada including vice president, Inflammation and Nephrology Business Unit. He was also a brand manager at Procter and Gamble Company.

Ted Raad, Pulmatrix chief executive officer, was quoted as stating; "We are delighted to welcome Anand to the Pulmatrix Board. Anand is a recognised leader in the biotech industry and his extensive experience in corporate strategy and commercialisation will be invaluable to Pulmatrix's future growth and success. I look forward to Anand's guidance as we execute on our vision to bring iSPERSE enabled inhaled therapies to patients with a broad range of large market indications. I'd also like to thank Mark for his invaluable contributions to Pulmatrix during his time on the board."